📑 Table of Contents
- Best Lung Cancer Treatment in India
- Lung Cancer Treatment Cost in India: By Modality
- Total Treatment Cost by Stage and Molecular Subtype
- Why Molecular Testing Is the Most Important First Step
- Surgical Options for Lung Cancer in India
- 7 Factors That Determine Your Lung Cancer Treatment Cost
- How to Get an Accurate Lung Cancer Treatment Estimate
Best Lung Cancer Treatment in India
Lung cancer treatment has changed more in the last decade than in the previous fifty years. The introduction of molecular testing, targeted therapies for specific gene mutations, and checkpoint inhibitor immunotherapy has shifted lung cancer from a disease with very limited systemic treatment options to one where, for a significant proportion of patients, effective long-term control is achievable.
India’s leading thoracic oncology programmes have fully adopted these advances. EGFR-targeted therapy, ALK inhibitors, PD-L1-guided immunotherapy, minimally invasive thoracic surgery (VATS), and stereotactic body radiation (SBRT) are all available at accredited Indian cancer centres — at a fraction of what the same treatment costs in the US, UK, or Gulf.
This guide covers what lung cancer treatment in India involves, what it costs by stage and molecular subtype, and what you need to know before getting a realistic estimate for your specific case.
Lung Cancer Treatment Cost in India: By Modality
All figures in USD at JCI or NABH-accredited hospitals with dedicated thoracic oncology programmes.
|
Treatment / Procedure |
India (USD) |
USA (USD) |
UK (USD) |
Saving vs USA |
|
SURGERY |
|
|
|
|
|
Lobectomy (open thoracotomy) |
$5,000–$8,500 |
$40,000–$90,000 |
$22,000–$50,000 |
~90% |
|
VATS Lobectomy (minimally invasive) |
$6,000–$10,000 |
$45,000–$100,000 |
$25,000–$55,000 |
~90% |
|
Pneumonectomy |
$6,500–$10,500 |
$45,000–$100,000 |
$25,000–$55,000 |
~90% |
|
Wedge Resection / Segmentectomy |
$4,500–$7,500 |
$30,000–$70,000 |
$18,000–$40,000 |
~89% |
|
Mediastinoscopy / Staging Biopsy |
$1,500–$3,000 |
$10,000–$25,000 |
$5,000–$14,000 |
~88% |
|
TARGETED THERAPY (per month) |
|
|
|
|
|
Gefitinib / generic Erlotinib (EGFR exon 19/21) |
$80–$200 |
$4,000–$8,000 |
$2,000–$5,000 |
~97% |
|
Osimertinib / Tagrisso (EGFR T790M) |
$800–$2,000 |
$18,000–$22,000 |
$9,000–$14,000 |
~93% |
|
Alectinib / Crizotinib (ALK-positive) |
$600–$1,800 |
$15,000–$20,000 |
$8,000–$12,000 |
~93% |
|
Sotorasib / Adagrasib (KRAS G12C) |
$2,500–$5,000 |
$20,000–$28,000 |
$12,000–$18,000 |
~85% |
|
IMMUNOTHERAPY (per cycle) |
|
|
|
|
|
Pembrolizumab (Keytruda) — 3-weekly |
$1,500–$3,500 |
$10,000–$15,000 |
$6,000–$10,000 |
~83% |
|
Nivolumab (Opdivo) — 2-weekly |
$1,200–$3,000 |
$9,000–$14,000 |
$5,000–$9,000 |
~83% |
|
Durvalumab (Imfinzi) — 4-weekly maintenance |
$1,200–$2,800 |
$9,000–$14,000 |
$5,000–$9,000 |
~83% |
|
CHEMOTHERAPY (per cycle) |
|
|
|
|
|
Carboplatin + Paclitaxel |
$300–$700 |
$3,000–$8,000 |
$1,500–$5,000 |
~92% |
|
Cisplatin + Pemetrexed (non-squamous) |
$400–$900 |
$4,000–$10,000 |
$2,000–$6,000 |
~92% |
|
Carbo + Pemetrexed + Pembrolizumab (combo) |
$2,000–$4,500 |
$14,000–$22,000 |
$8,000–$14,000 |
~84% |
|
RADIATION (full course) |
|
|
|
|
|
SBRT / SABR (3–5 fractions, early inoperable) |
$4,000–$7,000 |
$25,000–$60,000 |
$15,000–$35,000 |
~88% |
|
Concurrent Chemoradiation (Stage III, 30–35 fractions) |
$5,000–$9,000 |
$35,000–$80,000 |
$20,000–$45,000 |
~89% |
|
Palliative Radiation (symptom control) |
$1,200–$3,000 |
$8,000–$20,000 |
$4,000–$12,000 |
~87% |
Total Treatment Cost by Stage and Molecular Subtype
Lung cancer treatment cost is determined primarily by stage and molecular profile. A patient with early operable disease may complete treatment for $10,000–$18,000. A patient with Stage IV EGFR-mutant disease on generic erlotinib may spend under $2,500 per year. Here is a stage-by-stage summary:
|
Stage / Subtype |
Standard Treatment Protocol |
Estimated Total Cost in India (USD) |
|
Stage I–II — Operable NSCLC |
VATS lobectomy + adjuvant chemo (4 cycles) where indicated |
$10,000–$18,000 |
|
Stage I–II — Inoperable |
SBRT (3–5 fractions) as definitive treatment |
$4,000–$7,000 |
|
Stage III — Unresectable (no driver mutation) |
Concurrent chemoradiation + 12 months durvalumab maintenance |
$19,000–$43,000 total |
|
Stage IV — EGFR mutation (exon 19/21) |
Generic gefitinib or erlotinib oral daily, ongoing |
$960–$2,400 per year — most affordable scenario |
|
Stage IV — EGFR T790M resistance |
Osimertinib (Tagrisso) oral daily |
$9,600–$24,000 per year |
|
Stage IV — ALK-positive |
Alectinib or lorlatinib oral daily |
$8,000–$22,000 per year |
|
Stage IV — PD-L1 ≥50%, no driver mutation |
Pembrolizumab monotherapy, every 3 weeks, up to 2 years |
$26,000–$91,000 total (2 years); most stop earlier |
|
Stage IV — PD-L1 <50%, no driver mutation |
Carbo + pemetrexed + pembrolizumab induction then maintenance |
$22,000–$55,000 for induction; maintenance ongoing |
|
SCLC — Limited stage |
Cisplatin/etoposide + thoracic radiation + prophylactic cranial irradiation |
$8,000–$16,000 total |
Why Molecular Testing Is the Most Important First Step
Before any treatment plan can be finalised, molecular testing of the tumour tissue is essential. The results determine not just which drugs are appropriate, but whether chemotherapy should be used at all in early-line treatment.
Tests Required for Lung Cancer
- EGFR mutation testing — detects sensitising mutations in exons 19 and 21 (first-gen TKIs) and T790M resistance mutation (osimertinib)
- ALK rearrangement testing — ALK-positive NSCLC responds to crizotinib, alectinib, or lorlatinib; present in ~5% of NSCLC
- ROS1 rearrangement testing — responds to crizotinib and entrectinib
- KRAS G12C mutation testing — eligible for sotorasib or adagrasib
- PD-L1 expression testing (IHC) — determines whether pembrolizumab monotherapy is appropriate (PD-L1 ≥50%) or combination chemotherapy is needed
- BRAF, MET, RET, NTRK testing — less common but actionable with specific targeted agents
- Comprehensive NGS panel — covers all above in one test; available in India for $400–$1,200; results in 10–15 days
|
The Single Most Important Cost Variable in Lung Cancer A patient with EGFR-mutant Stage IV lung cancer on generic erlotinib in India may spend $960–$2,400 per year. A patient with the same stage, no driver mutation, and low PD-L1 on combination immunochemotherapy may spend $22,000–$55,000 for induction alone. Molecular testing results, not stage alone, determine the cost most significantly for Stage III–IV lung cancer. |
Surgical Options for Lung Cancer in India
Surgery is the primary treatment for Stage I and II NSCLC in patients fit enough to undergo the procedure. India’s leading thoracic centres offer both open thoracotomy and minimally invasive VATS approaches.
VATS vs Open Thoracotomy
VATS lobectomy involves three or four small incisions rather than a large thoracotomy wound, resulting in less post-operative pain, shorter hospital stay (5–7 vs 7–10 days), and faster recovery. VATS costs $6,000–$10,000 vs $5,000–$8,500 for open — the modest premium is usually justified by clinical advantages. Not all tumours are suitable for VATS; your thoracic surgeon will advise based on CT and PET imaging.
Post-Surgical Adjuvant Treatment
Following lobectomy for Stage II and selected Stage IB NSCLC, 4 cycles of adjuvant chemotherapy are recommended — adding $1,200–$3,600 to total cost. For EGFR-mutant Stage IB–IIIA patients, adjuvant osimertinib for 3 years is now guideline-recommended (ADAURA trial), adding $28,800–$72,000 to post-surgical cost. Confirm with your oncologist whether this applies to your case.
7 Factors That Determine Your Lung Cancer Treatment Cost
|
1 |
Stage at Diagnosis Stage I–II operable disease has a defined one-time surgical cost. Stage III requires combined chemoradiation plus immunotherapy maintenance. Stage IV requires ongoing systemic therapy with monthly costs that continue until progression. Stage determines the cost structure. |
|
2 |
Molecular Profile EGFR mutation on generic TKI is the most affordable systemic treatment: $80–$200 per month. ALK-positive on alectinib costs $600–$1,800 per month. PD-L1-high on pembrolizumab costs $1,500–$3,500 per cycle. The molecular result drives cost more than any other factor for Stage III–IV disease. |
|
3 |
VATS vs Open Surgery VATS adds $1,000–$2,000 over open surgery but reduces hospital stay by 3–5 days. Total cost difference is often neutral once shorter stay is factored in. |
|
4 |
Radiation Modality SBRT for early inoperable disease (3–5 fractions) costs $4,000–$7,000. Concurrent chemoradiation for Stage III costs $5,000–$9,000 for radiation alone. Palliative radiation for metastatic disease is lower cost but billed separately. |
|
5 |
Duration of Systemic Therapy Oral targeted therapies continue until progression or toxicity. EGFR first-gen TKI response averages 10–14 months before T790M resistance develops, requiring switch to osimertinib. Total targeted therapy cost depends on response duration, which is not predictable in advance. |
|
6 |
Immunotherapy Duration Pembrolizumab is approved for up to 2 years in NSCLC. Many patients stop earlier due to progression or immune-related adverse events. Budget for protocol duration but understand actual cost depends on treatment response. |
|
7 |
Performance Status and Co-Morbidities Patients with reduced lung function (COPD), cardiovascular disease, or poor performance status may require modified protocols or may not be eligible for certain approaches. This can affect both treatment plan and cost. |
How to Get an Accurate Lung Cancer Treatment Estimate
- Gather your complete diagnostic file: CT chest and abdomen, PET-CT if available, bronchoscopy biopsy pathology, and any molecular profiling already done
- If you have tissue from a biopsy but no molecular testing, ask whether the block can be sent to India for testing before you travel
- Share your reports for an oncologist review before requesting cost — stage, histology, and molecular profile are all required for a meaningful estimate
- Confirm whether your case will be reviewed by a multidisciplinary thoracic tumour board involving thoracic surgeon, medical oncologist, and radiation oncologist
- For Stage III–IV disease, ask for the first-line regimen recommended, expected number of cycles or treatment duration, and response monitoring schedule
- Arrange a video consultation with the treating thoracic oncologist before committing to travel
- Confirm whether adjuvant osimertinib is being recommended post-surgery if you have EGFR-mutant Stage IB–IIIA disease — this is a significant additional cost commitment
|
Get a Personalised Lung Cancer Treatment Plan and Cost Estimate Lung cancer treatment cost in India depends on your stage, histology, and molecular profile. The difference between an EGFR-mutant patient on generic TKI and a PD-L1-negative patient on combination immunochemotherapy is $1,000 versus $30,000+ per year. An accurate estimate requires a specialist’s review of your biopsy, molecular testing, and imaging. Share your pathology, molecular testing, and CT / PET-CT reports with our team. A matched thoracic oncologist will review your case and provide a written treatment plan and itemised cost estimate — free of charge, with no obligation to proceed. Free. Confidential. Reports reviewed within 24–48 hours. | www.racurehealthcare.com |
🫀 Need Expert Cardiac Care?
Our experienced cardiac surgeons can help you understand your options and plan the best treatment.
